Medicinal Chemistry of Metal Complexes: Design, Synthesis and Evaluation

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 25 June 2025 | Viewed by 1349

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemistry, Institute of Chemistry, Technology and Metallurgy—National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia
Interests: coordination complexes; inorganic biochemistry; medicinal chemistry; biological activity; drug design

Special Issue Information

Dear Colleagues,

Metal-based drugs and metal complexes continue to be of great interest in medicinal chemistry due to their diversity in biological application. They can play a key role in various biochemical processes in living beings and are essential for catalysis, photochemistry, etc., in biological systems.

Throughout history, metal-based drugs have been used, but the discovery of cisplatin was a breakthrough moment that motivated researchers to design and synthesize more metal complexes for use in biological treatment. Platinum-based drugs, especially cisplatin, are undoubtedly the most commonly used metal complexes in the treatment of cancer, but a large number of complex compounds based on other metals (palladium, gold, ruthenium, silver, tin, rhodium, etc.) are also used as antitumor drugs.

This Special Issue, “Medicinal Chemistry of Metal Complexes: Design, Synthesis and Evaluation”, focuses on the growing knowledge in coordination chemistry that is crucial for the design of new compounds for therapeutic and diagnostic use, such as in cancer, diabetes, Parkinson’s and Alzheimer’s disease therapy, or any other use of metal-based drugs as possible medicines for a biological targets in living organisms. The evaluation can additionally refer to any interesting features of metal complexes such as their optical, magnetic, electrical, crystal or even nanostructure properties.

Here, we welcome original research articles and reviews. It is of great value to clearly organize the presented data, so that the article is easy to read even for researchers outside this field.

We look forward to receiving your contributions.

Dr. Bojana B. Zmejkovski
Prof. Dr. Goran Kaluđerović
Dr. Nebojša Pantelić
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metal complexes
  • medicinal chemistry
  • bioinorganic chemistry
  • coordination chemistry
  • organometallics
  • metal-based drugs
  • biological activity
  • toxicology
  • biomedical application
  • drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1566 KiB  
Article
Synthesis and Evaluation of Cytotoxic Activity of RuCp(II) Complexes Bearing (Iso)nicotinic Acid Based Ligands
by Bárbara Marques, Diogo M. Engrácia, João Franco Machado, Jaime A. S. Coelho, Filipa Mendes and Tânia S. Morais
Pharmaceuticals 2025, 18(1), 97; https://doi.org/10.3390/ph18010097 - 14 Jan 2025
Viewed by 955
Abstract
Background/Objectives: Cancer remains one of the major challenges of our century. Organometallic ruthenium complexes are gaining recognition as a highly promising group of compounds in the development of cancer treatments. Methods: Building on the auspicious results obtained for [Ru(η5-C5H [...] Read more.
Background/Objectives: Cancer remains one of the major challenges of our century. Organometallic ruthenium complexes are gaining recognition as a highly promising group of compounds in the development of cancer treatments. Methods: Building on the auspicious results obtained for [Ru(η5-C5H5)(PPh3)(bipy)][CF3SO3] (TM34), our focus has shifted to examining the effects of incorporating bioactive ligands into the TM34 framework, particularly within the cyclopentadienyl ring. Results: In this study, we report the synthesis and characterization of two new ruthenium(II) complexes with the general formula [Ru(η5-C5H4CCH3=R)(PPh3)(bipy)][CF3SO3], where R represents a nicotinic acid derivative (NNHCO(py-3-yl)) (1) or an isoniazid derivative (NNHCO(py-4-yl)) (2). The complexes were fully characterized using a combination of spectroscopic techniques and computational analysis, revealing the presence of E/Z-hydrazone isomerism. Stability studies confirmed the robustness of both complexes in biological media, with compound 1 maintaining good stability in buffer solutions mimicking physiological (pH 7.4) and tumor-like (pH 6.8) environments. The cytotoxicity of the complexes was evaluated in vitro in several human cancer cell lines, namely melanoma (A375), alveolar adenocarcinoma (A549), epidermoid carcinoma (A431), and breast cancer (MDA-MB 231). Conclusions: Both compounds exhibited moderate to high cytotoxic activity, with complex 1 showing a greater propensity to induce cell death, particularly in the A431 and MDA-MB 231 cell lines. Full article
Show Figures

Graphical abstract

Back to TopTop